The course of lung oligometastatic colorectal cancer may be a reflection of selection for treatment rather than an effect of stereotactic body radiotherapy-Reference-Cited by-同舟云学术

The course of lung oligometastatic colorectal cancer may be a reflection of selection for treatment rather than an effect of stereotactic body radiotherapy

Published:2020-11-26 Issue:1 Volume:197 Page:74-75
ISSN:0179-7158
Container-title:Strahlentherapie und Onkologie
language:en
Short-container-title:Strahlenther Onkol

Author:

Macbeth Fergus,Treasure Tom^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Radiology, Nuclear Medicine and imaging

Link

http://link.springer.com/content/pdf/10.1007/s00066-020-01709-6.pdf

Reference6 articles.

1. Nicosia L, Cuccia F, Mazzola R, Ricchetti F, Figlia V, Giaj-Levra N et al (2020) Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy. Strahlenther Onkol 196(9):813–820

2. Treasure T (2012) Oligometastatic cancer: an entity, a useful concept, or a therapeutic opportunity? J R Soc Med 105(6):242–246

3. Milosevic M, Edwards J, Tsang D, Dunning J, Shackcloth M, Batchelor T et al (2020) Pulmonary metastasectomy in colorectal cancer: updated analysis of 93 randomized patients—control survival is much better than previously assumed. Colorectal Dis 22(10):1314–1324. https://doi.org/10.1111/codi.15113

4. Ruers T, van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA et al (2017) Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst 109(9):djx15

5. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393(10185):2051–2058

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stereotactic Ablative Radiotherapy for Oligometastatic Disease: Great Enthusiasm but Scant Evidence;Clinical Oncology;2022-05